Literature DB >> 15534593

Stem cells to replace the optic nerve.

H A Quigley1, D S Iglesia.   

Abstract

Methods that exist now and that might be developed are suggested to replace retinal ganglion cells and their axons in the optic nerve, ultimately to re-establish functional vision in eyes blind from glaucoma.

Entities:  

Mesh：

Year:  2004        PMID： 15534593     DOI： 10.1038/sj.eye.6701577

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


  6 in total

1.  A new immunodeficient retinal dystrophic rat model for transplantation studies using human-derived cells.

Authors:  Biju B Thomas; Danhong Zhu; Tai-Chi Lin; Young Chang Kim; Magdalene J Seiler; Juan Carlos Martinez-Camarillo; Bin Lin; Yousuf Shad; David R Hinton; Mark S Humayun
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-09-13       Impact factor: 3.117

2.  Minimally-invasive Technique for Injection into Rat Optic Nerve.

Authors:  Kateryna Raykova; Melina V Jones; Hwa Huang; Paul F Hoffman; Michael Levy
Journal:  J Vis Exp       Date:  2015-05-19       Impact factor: 1.355

3.  Stem cell therapy for glaucoma: possibilities and practicalities.

Authors:  Thomas V Johnson; Natalie D Bull; Keith R Martin
Journal:  Expert Rev Ophthalmol       Date:  2011-04-01

4.  Broadening our focus in the search for cell transplantation-based glaucoma therapies.

Authors:  T V Johnson; K R Martin
Journal:  Eye (Lond)       Date:  2011-05       Impact factor: 3.775

5.  Donation of mitochondria by iPSC-derived mesenchymal stem cells protects retinal ganglion cells against mitochondrial complex I defect-induced degeneration.

Authors:  Dan Jiang; Guoyin Xiong; Hong Feng; Zhao Zhang; Peikai Chen; Bin Yan; Ling Chen; Kesavamoorthy Gandhervin; Chuiyan Ma; Cheng Li; Shuo Han; Yuelin Zhang; Can Liao; Tin-Lap Lee; Hung-Fat Tse; Qing-Ling Fu; Kin Chiu; Qizhou Lian
Journal:  Theranostics       Date:  2019-04-13       Impact factor: 11.556

6.  Intravitreal autologous mesenchymal stem cell transplantation: a non-randomized phase I clinical trial in patients with retinitis pigmentosa.

Authors:  Aekkachai Tuekprakhon; Siripakorn Sangkitporn; Adisak Trinavarat; Aulia Rahmi Pawestri; Visit Vamvanij; Monchai Ruangchainikom; Panya Luksanapruksa; Phitchapa Pongpaksupasin; Areerat Khorchai; Acharaporn Dambua; Patcharaporn Boonchu; Chonlada Yodtup; Mongkol Uiprasertkul; Somchai Sangkitporn; La-Ongsri Atchaneeyasakul
Journal:  Stem Cell Res Ther       Date:  2021-01-09       Impact factor: 6.832
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.